nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—CYP3A4—bone cancer	0.648	1	CbGaD
Cabergoline—HTR1B—dura mater—bone cancer	0.0207	0.168	CbGeAlD
Cabergoline—HTR1D—dura mater—bone cancer	0.0201	0.163	CbGeAlD
Cabergoline—DRD5—eyelid—bone cancer	0.0197	0.16	CbGeAlD
Cabergoline—HTR1B—trigeminal nerve—bone cancer	0.00891	0.0724	CbGeAlD
Cabergoline—HTR1D—trigeminal nerve—bone cancer	0.00863	0.0701	CbGeAlD
Cabergoline—HTR1B—cranial nerve—bone cancer	0.00635	0.0516	CbGeAlD
Cabergoline—HTR1D—cranial nerve—bone cancer	0.00615	0.0499	CbGeAlD
Cabergoline—HTR7—cranial nerve—bone cancer	0.0049	0.0398	CbGeAlD
Cabergoline—HTR2A—trigeminal nerve—bone cancer	0.00429	0.0348	CbGeAlD
Cabergoline—HTR2A—cranial nerve—bone cancer	0.00305	0.0248	CbGeAlD
Cabergoline—HTR2A—vertebral column—bone cancer	0.003	0.0243	CbGeAlD
Cabergoline—Leg edema—Doxorubicin—bone cancer	0.00279	0.0192	CcSEcCtD
Cabergoline—HTR2A—hindlimb—bone cancer	0.00257	0.0209	CbGeAlD
Cabergoline—HTR2A—appendage—bone cancer	0.00221	0.0179	CbGeAlD
Cabergoline—Pericardial effusion—Methotrexate—bone cancer	0.00212	0.0146	CcSEcCtD
Cabergoline—Pericarditis—Methotrexate—bone cancer	0.00201	0.0138	CcSEcCtD
Cabergoline—Pericardial effusion—Epirubicin—bone cancer	0.00198	0.0136	CcSEcCtD
Cabergoline—Pulmonary fibrosis—Methotrexate—bone cancer	0.00198	0.0136	CcSEcCtD
Cabergoline—Pergolide—CYP3A4—bone cancer	0.00196	0.535	CrCbGaD
Cabergoline—Prostatic disorder—Epirubicin—bone cancer	0.00191	0.0132	CcSEcCtD
Cabergoline—Pericarditis—Epirubicin—bone cancer	0.00188	0.0129	CcSEcCtD
Cabergoline—Pericardial effusion—Doxorubicin—bone cancer	0.00183	0.0126	CcSEcCtD
Cabergoline—Prostatic disorder—Doxorubicin—bone cancer	0.00177	0.0122	CcSEcCtD
Cabergoline—Pericarditis—Doxorubicin—bone cancer	0.00174	0.012	CcSEcCtD
Cabergoline—Lisuride—CYP3A4—bone cancer	0.0017	0.465	CrCbGaD
Cabergoline—Pain—Carboplatin—bone cancer	0.00165	0.0113	CcSEcCtD
Cabergoline—HTR1D—connective tissue—bone cancer	0.00127	0.0103	CbGeAlD
Cabergoline—Nasal congestion—Cisplatin—bone cancer	0.00126	0.00868	CcSEcCtD
Cabergoline—ADRB1—connective tissue—bone cancer	0.00123	0.01	CbGeAlD
Cabergoline—Hypokinesia—Epirubicin—bone cancer	0.0012	0.00829	CcSEcCtD
Cabergoline—Pleural effusion—Methotrexate—bone cancer	0.00113	0.00781	CcSEcCtD
Cabergoline—Hypokinesia—Doxorubicin—bone cancer	0.00111	0.00767	CcSEcCtD
Cabergoline—Face oedema—Cisplatin—bone cancer	0.00111	0.00764	CcSEcCtD
Cabergoline—Blood creatinine increased—Cisplatin—bone cancer	0.00108	0.00741	CcSEcCtD
Cabergoline—Pleural effusion—Epirubicin—bone cancer	0.00106	0.00731	CcSEcCtD
Cabergoline—Orthostatic hypotension—Cisplatin—bone cancer	0.00105	0.00723	CcSEcCtD
Cabergoline—HTR7—connective tissue—bone cancer	0.00101	0.00821	CbGeAlD
Cabergoline—Pleural effusion—Doxorubicin—bone cancer	0.000983	0.00676	CcSEcCtD
Cabergoline—Sweating increased—Cisplatin—bone cancer	0.000968	0.00666	CcSEcCtD
Cabergoline—Abdominal discomfort—Cisplatin—bone cancer	0.000952	0.00656	CcSEcCtD
Cabergoline—Neoplasm malignant—Epirubicin—bone cancer	0.000952	0.00655	CcSEcCtD
Cabergoline—Breast pain—Epirubicin—bone cancer	0.000932	0.00642	CcSEcCtD
Cabergoline—Arthropathy—Epirubicin—bone cancer	0.000894	0.00616	CcSEcCtD
Cabergoline—Respiratory failure—Methotrexate—bone cancer	0.000885	0.00609	CcSEcCtD
Cabergoline—Neoplasm malignant—Doxorubicin—bone cancer	0.000881	0.00606	CcSEcCtD
Cabergoline—HTR1B—spinal cord—bone cancer	0.000869	0.00705	CbGeAlD
Cabergoline—Dyskinesia—Epirubicin—bone cancer	0.000865	0.00596	CcSEcCtD
Cabergoline—Breast pain—Doxorubicin—bone cancer	0.000862	0.00594	CcSEcCtD
Cabergoline—HTR2C—spinal cord—bone cancer	0.000833	0.00676	CbGeAlD
Cabergoline—Arthropathy—Doxorubicin—bone cancer	0.000827	0.0057	CcSEcCtD
Cabergoline—Musculoskeletal pain—Epirubicin—bone cancer	0.000823	0.00567	CcSEcCtD
Cabergoline—HTR2B—tendon—bone cancer	0.000811	0.00659	CbGeAlD
Cabergoline—Dyskinesia—Doxorubicin—bone cancer	0.000801	0.00551	CcSEcCtD
Cabergoline—Influenza like illness—Epirubicin—bone cancer	0.00079	0.00544	CcSEcCtD
Cabergoline—Visual impairment—Cisplatin—bone cancer	0.000766	0.00527	CcSEcCtD
Cabergoline—Musculoskeletal pain—Doxorubicin—bone cancer	0.000762	0.00524	CcSEcCtD
Cabergoline—Cramps of lower extremities—Epirubicin—bone cancer	0.000747	0.00514	CcSEcCtD
Cabergoline—ADRA2A—connective tissue—bone cancer	0.000741	0.00602	CbGeAlD
Cabergoline—Cardiac disorder—Cisplatin—bone cancer	0.000738	0.00508	CcSEcCtD
Cabergoline—Influenza like illness—Doxorubicin—bone cancer	0.000731	0.00503	CcSEcCtD
Cabergoline—Arrhythmia—Cisplatin—bone cancer	0.00071	0.00489	CcSEcCtD
Cabergoline—Abnormal vision—Epirubicin—bone cancer	0.000709	0.00488	CcSEcCtD
Cabergoline—Mental disability—Epirubicin—bone cancer	0.000706	0.00486	CcSEcCtD
Cabergoline—Alopecia—Cisplatin—bone cancer	0.000703	0.00484	CcSEcCtD
Cabergoline—HTR1A—spinal cord—bone cancer	0.000701	0.00569	CbGeAlD
Cabergoline—HTR7—tendon—bone cancer	0.000695	0.00564	CbGeAlD
Cabergoline—Cramps of lower extremities—Doxorubicin—bone cancer	0.000691	0.00476	CcSEcCtD
Cabergoline—Flatulence—Cisplatin—bone cancer	0.000682	0.00469	CcSEcCtD
Cabergoline—Hepatic function abnormal—Epirubicin—bone cancer	0.000675	0.00465	CcSEcCtD
Cabergoline—HTR7—spinal cord—bone cancer	0.00067	0.00544	CbGeAlD
Cabergoline—Muscle spasms—Cisplatin—bone cancer	0.000666	0.00458	CcSEcCtD
Cabergoline—Abnormal vision—Doxorubicin—bone cancer	0.000656	0.00452	CcSEcCtD
Cabergoline—Mental disability—Doxorubicin—bone cancer	0.000653	0.00449	CcSEcCtD
Cabergoline—Ill-defined disorder—Cisplatin—bone cancer	0.000642	0.00442	CcSEcCtD
Cabergoline—ADRA2C—tendon—bone cancer	0.000639	0.00518	CbGeAlD
Cabergoline—Hot flush—Epirubicin—bone cancer	0.000631	0.00434	CcSEcCtD
Cabergoline—Osteoarthritis—Methotrexate—bone cancer	0.000631	0.00434	CcSEcCtD
Cabergoline—HTR2A—connective tissue—bone cancer	0.00063	0.00512	CbGeAlD
Cabergoline—Menopausal symptoms—Epirubicin—bone cancer	0.000626	0.00431	CcSEcCtD
Cabergoline—Hepatic function abnormal—Doxorubicin—bone cancer	0.000625	0.0043	CcSEcCtD
Cabergoline—Malaise—Cisplatin—bone cancer	0.000624	0.0043	CcSEcCtD
Cabergoline—ADRA2C—spinal cord—bone cancer	0.000616	0.005	CbGeAlD
Cabergoline—Cardiac failure—Epirubicin—bone cancer	0.000605	0.00416	CcSEcCtD
Cabergoline—Osteoarthritis—Epirubicin—bone cancer	0.00059	0.00406	CcSEcCtD
Cabergoline—Anxiety—Cisplatin—bone cancer	0.000587	0.00404	CcSEcCtD
Cabergoline—Hot flush—Doxorubicin—bone cancer	0.000584	0.00402	CcSEcCtD
Cabergoline—Liver function test abnormal—Methotrexate—bone cancer	0.000582	0.00401	CcSEcCtD
Cabergoline—Discomfort—Cisplatin—bone cancer	0.000582	0.00401	CcSEcCtD
Cabergoline—Menopausal symptoms—Doxorubicin—bone cancer	0.000579	0.00398	CcSEcCtD
Cabergoline—Face oedema—Epirubicin—bone cancer	0.00057	0.00392	CcSEcCtD
Cabergoline—Oedema—Cisplatin—bone cancer	0.000565	0.00389	CcSEcCtD
Cabergoline—Cardiac failure—Doxorubicin—bone cancer	0.00056	0.00385	CcSEcCtD
Cabergoline—Blood creatinine increased—Epirubicin—bone cancer	0.000553	0.00381	CcSEcCtD
Cabergoline—Osteoarthritis—Doxorubicin—bone cancer	0.000546	0.00376	CcSEcCtD
Cabergoline—Hyperhidrosis—Cisplatin—bone cancer	0.000546	0.00376	CcSEcCtD
Cabergoline—Liver function test abnormal—Epirubicin—bone cancer	0.000545	0.00375	CcSEcCtD
Cabergoline—Orthostatic hypotension—Epirubicin—bone cancer	0.000539	0.00371	CcSEcCtD
Cabergoline—Abdominal pain upper—Epirubicin—bone cancer	0.000539	0.00371	CcSEcCtD
Cabergoline—Anorexia—Cisplatin—bone cancer	0.000539	0.00371	CcSEcCtD
Cabergoline—Hypotension—Cisplatin—bone cancer	0.000528	0.00363	CcSEcCtD
Cabergoline—Face oedema—Doxorubicin—bone cancer	0.000527	0.00363	CcSEcCtD
Cabergoline—Abdominal discomfort—Methotrexate—bone cancer	0.000523	0.0036	CcSEcCtD
Cabergoline—Gastritis—Epirubicin—bone cancer	0.000522	0.0036	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000515	0.00354	CcSEcCtD
Cabergoline—Blood creatinine increased—Doxorubicin—bone cancer	0.000512	0.00352	CcSEcCtD
Cabergoline—Influenza—Epirubicin—bone cancer	0.00051	0.00351	CcSEcCtD
Cabergoline—ADRA2A—tendon—bone cancer	0.00051	0.00414	CbGeAlD
Cabergoline—Paraesthesia—Cisplatin—bone cancer	0.000507	0.00349	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Methotrexate—bone cancer	0.000507	0.00349	CcSEcCtD
Cabergoline—Liver function test abnormal—Doxorubicin—bone cancer	0.000504	0.00347	CcSEcCtD
Cabergoline—Dyspnoea—Cisplatin—bone cancer	0.000504	0.00347	CcSEcCtD
Cabergoline—Orthostatic hypotension—Doxorubicin—bone cancer	0.000499	0.00343	CcSEcCtD
Cabergoline—Abdominal pain upper—Doxorubicin—bone cancer	0.000499	0.00343	CcSEcCtD
Cabergoline—ADRA2A—spinal cord—bone cancer	0.000491	0.00399	CbGeAlD
Cabergoline—Decreased appetite—Cisplatin—bone cancer	0.000491	0.00338	CcSEcCtD
Cabergoline—Bronchitis—Epirubicin—bone cancer	0.000491	0.00338	CcSEcCtD
Cabergoline—Pneumonia—Methotrexate—bone cancer	0.000489	0.00337	CcSEcCtD
Cabergoline—Depression—Methotrexate—bone cancer	0.000485	0.00334	CcSEcCtD
Cabergoline—Gastritis—Doxorubicin—bone cancer	0.000483	0.00333	CcSEcCtD
Cabergoline—Pain—Cisplatin—bone cancer	0.000483	0.00333	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Epirubicin—bone cancer	0.000474	0.00326	CcSEcCtD
Cabergoline—Influenza—Doxorubicin—bone cancer	0.000472	0.00325	CcSEcCtD
Cabergoline—Feeling abnormal—Cisplatin—bone cancer	0.000466	0.0032	CcSEcCtD
Cabergoline—Weight increased—Epirubicin—bone cancer	0.000464	0.0032	CcSEcCtD
Cabergoline—Weight decreased—Epirubicin—bone cancer	0.000462	0.00318	CcSEcCtD
Cabergoline—Epistaxis—Methotrexate—bone cancer	0.000458	0.00316	CcSEcCtD
Cabergoline—Pneumonia—Epirubicin—bone cancer	0.000458	0.00315	CcSEcCtD
Cabergoline—Bronchitis—Doxorubicin—bone cancer	0.000454	0.00312	CcSEcCtD
Cabergoline—Urinary tract infection—Epirubicin—bone cancer	0.000442	0.00304	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000439	0.00302	CcSEcCtD
Cabergoline—HTR2A—tendon—bone cancer	0.000433	0.00352	CbGeAlD
Cabergoline—Weight increased—Doxorubicin—bone cancer	0.00043	0.00296	CcSEcCtD
Cabergoline—Epistaxis—Epirubicin—bone cancer	0.000429	0.00295	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—bone cancer	0.000427	0.00294	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—bone cancer	0.000423	0.00291	CcSEcCtD
Cabergoline—Visual impairment—Methotrexate—bone cancer	0.000421	0.00289	CcSEcCtD
Cabergoline—HTR2A—spinal cord—bone cancer	0.000418	0.00339	CbGeAlD
Cabergoline—Hypersensitivity—Cisplatin—bone cancer	0.000416	0.00286	CcSEcCtD
Cabergoline—Rhinitis—Epirubicin—bone cancer	0.000409	0.00282	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—bone cancer	0.000409	0.00282	CcSEcCtD
Cabergoline—Asthenia—Cisplatin—bone cancer	0.000405	0.00279	CcSEcCtD
Cabergoline—Cardiac disorder—Methotrexate—bone cancer	0.000405	0.00279	CcSEcCtD
Cabergoline—Oedema peripheral—Epirubicin—bone cancer	0.000402	0.00277	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—bone cancer	0.000397	0.00273	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—bone cancer	0.000394	0.00271	CcSEcCtD
Cabergoline—Diarrhoea—Cisplatin—bone cancer	0.000387	0.00266	CcSEcCtD
Cabergoline—Alopecia—Methotrexate—bone cancer	0.000386	0.00265	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—bone cancer	0.000379	0.00261	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—bone cancer	0.000379	0.00261	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—bone cancer	0.000372	0.00256	CcSEcCtD
Cabergoline—Back pain—Methotrexate—bone cancer	0.000367	0.00253	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—bone cancer	0.000365	0.00251	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—bone cancer	0.000364	0.00251	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—bone cancer	0.000361	0.00248	CcSEcCtD
Cabergoline—Vomiting—Cisplatin—bone cancer	0.000359	0.00247	CcSEcCtD
Cabergoline—Rash—Cisplatin—bone cancer	0.000356	0.00245	CcSEcCtD
Cabergoline—Dermatitis—Cisplatin—bone cancer	0.000356	0.00245	CcSEcCtD
Cabergoline—Ill-defined disorder—Methotrexate—bone cancer	0.000352	0.00243	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—bone cancer	0.000351	0.00241	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—bone cancer	0.00035	0.00241	CcSEcCtD
Cabergoline—Tension—Epirubicin—bone cancer	0.000349	0.0024	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—bone cancer	0.000345	0.00238	CcSEcCtD
Cabergoline—Back pain—Epirubicin—bone cancer	0.000344	0.00237	CcSEcCtD
Cabergoline—Malaise—Methotrexate—bone cancer	0.000343	0.00236	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—bone cancer	0.000342	0.00235	CcSEcCtD
Cabergoline—Vertigo—Methotrexate—bone cancer	0.000341	0.00235	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—bone cancer	0.000338	0.00232	CcSEcCtD
Cabergoline—Nausea—Cisplatin—bone cancer	0.000336	0.00231	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—bone cancer	0.000334	0.0023	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—bone cancer	0.00033	0.00227	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—bone cancer	0.000324	0.00223	CcSEcCtD
Cabergoline—Arthralgia—Methotrexate—bone cancer	0.000323	0.00223	CcSEcCtD
Cabergoline—Tension—Doxorubicin—bone cancer	0.000323	0.00222	CcSEcCtD
Cabergoline—Malaise—Epirubicin—bone cancer	0.000321	0.00221	CcSEcCtD
Cabergoline—Discomfort—Methotrexate—bone cancer	0.00032	0.0022	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—bone cancer	0.000319	0.0022	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—bone cancer	0.000319	0.0022	CcSEcCtD
Cabergoline—Syncope—Epirubicin—bone cancer	0.000319	0.00219	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—bone cancer	0.000318	0.00219	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—bone cancer	0.000316	0.00218	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—bone cancer	0.000314	0.00216	CcSEcCtD
Cabergoline—Confusional state—Methotrexate—bone cancer	0.000313	0.00215	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—bone cancer	0.000312	0.00215	CcSEcCtD
Cabergoline—Hypertension—Epirubicin—bone cancer	0.000307	0.00211	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—bone cancer	0.000305	0.0021	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—bone cancer	0.000303	0.00208	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—bone cancer	0.000302	0.00208	CcSEcCtD
Cabergoline—Hyperhidrosis—Methotrexate—bone cancer	0.0003	0.00206	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—bone cancer	0.000299	0.00206	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—bone cancer	0.000297	0.00204	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—bone cancer	0.000296	0.00204	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—bone cancer	0.000296	0.00203	CcSEcCtD
Cabergoline—Anorexia—Methotrexate—bone cancer	0.000296	0.00203	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—bone cancer	0.000295	0.00203	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—bone cancer	0.000293	0.00201	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—bone cancer	0.000291	0.002	CcSEcCtD
Cabergoline—Oedema—Epirubicin—bone cancer	0.00029	0.002	CcSEcCtD
Cabergoline—Hypotension—Methotrexate—bone cancer	0.00029	0.00199	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—bone cancer	0.000289	0.00199	CcSEcCtD
Cabergoline—Shock—Epirubicin—bone cancer	0.000285	0.00196	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—bone cancer	0.000284	0.00195	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000282	0.00194	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—bone cancer	0.00028	0.00193	CcSEcCtD
Cabergoline—Insomnia—Methotrexate—bone cancer	0.00028	0.00193	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—bone cancer	0.00028	0.00193	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—bone cancer	0.000279	0.00192	CcSEcCtD
Cabergoline—Paraesthesia—Methotrexate—bone cancer	0.000278	0.00192	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—bone cancer	0.000277	0.0019	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—bone cancer	0.000277	0.0019	CcSEcCtD
Cabergoline—Dyspnoea—Methotrexate—bone cancer	0.000276	0.0019	CcSEcCtD
Cabergoline—Somnolence—Methotrexate—bone cancer	0.000276	0.0019	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—bone cancer	0.000274	0.00189	CcSEcCtD
Cabergoline—Dyspepsia—Methotrexate—bone cancer	0.000273	0.00188	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—bone cancer	0.000271	0.00187	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—bone cancer	0.000271	0.00186	CcSEcCtD
Cabergoline—Decreased appetite—Methotrexate—bone cancer	0.000269	0.00185	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—bone cancer	0.000268	0.00185	CcSEcCtD
Cabergoline—Fatigue—Methotrexate—bone cancer	0.000267	0.00184	CcSEcCtD
Cabergoline—Pain—Methotrexate—bone cancer	0.000265	0.00182	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000264	0.00182	CcSEcCtD
Cabergoline—Shock—Doxorubicin—bone cancer	0.000264	0.00182	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—bone cancer	0.000262	0.00181	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—bone cancer	0.000261	0.00179	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—bone cancer	0.00026	0.00179	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—bone cancer	0.000259	0.00178	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—bone cancer	0.000258	0.00178	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—bone cancer	0.000256	0.00176	CcSEcCtD
Cabergoline—Feeling abnormal—Methotrexate—bone cancer	0.000255	0.00176	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—bone cancer	0.000255	0.00176	CcSEcCtD
Cabergoline—Gastrointestinal pain—Methotrexate—bone cancer	0.000254	0.00174	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—bone cancer	0.000252	0.00174	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—bone cancer	0.000251	0.00173	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—bone cancer	0.00025	0.00172	CcSEcCtD
Cabergoline—Pain—Epirubicin—bone cancer	0.000248	0.00171	CcSEcCtD
Cabergoline—Constipation—Epirubicin—bone cancer	0.000248	0.00171	CcSEcCtD
Cabergoline—Abdominal pain—Methotrexate—bone cancer	0.000245	0.00169	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000245	0.00168	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—bone cancer	0.000243	0.00167	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—bone cancer	0.000241	0.00166	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—bone cancer	0.000239	0.00165	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—bone cancer	0.000239	0.00165	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—bone cancer	0.000239	0.00164	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—bone cancer	0.000237	0.00163	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—bone cancer	0.000236	0.00163	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—bone cancer	0.000233	0.00161	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—bone cancer	0.000231	0.00159	CcSEcCtD
Cabergoline—Pain—Doxorubicin—bone cancer	0.00023	0.00158	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—bone cancer	0.00023	0.00158	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—bone cancer	0.000229	0.00158	CcSEcCtD
Cabergoline—Hypersensitivity—Methotrexate—bone cancer	0.000228	0.00157	CcSEcCtD
Cabergoline—Asthenia—Methotrexate—bone cancer	0.000222	0.00153	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—bone cancer	0.000221	0.00152	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—bone cancer	0.00022	0.00151	CcSEcCtD
Cabergoline—Pruritus—Methotrexate—bone cancer	0.000219	0.00151	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—bone cancer	0.000214	0.00147	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—bone cancer	0.000212	0.00146	CcSEcCtD
Cabergoline—Diarrhoea—Methotrexate—bone cancer	0.000212	0.00146	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—bone cancer	0.000208	0.00143	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—bone cancer	0.000205	0.00141	CcSEcCtD
Cabergoline—Dizziness—Methotrexate—bone cancer	0.000205	0.00141	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—bone cancer	0.000199	0.00137	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—bone cancer	0.000198	0.00136	CcSEcCtD
Cabergoline—Vomiting—Methotrexate—bone cancer	0.000197	0.00136	CcSEcCtD
Cabergoline—Rash—Methotrexate—bone cancer	0.000195	0.00135	CcSEcCtD
Cabergoline—Dermatitis—Methotrexate—bone cancer	0.000195	0.00134	CcSEcCtD
Cabergoline—Headache—Methotrexate—bone cancer	0.000194	0.00134	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—bone cancer	0.000193	0.00133	CcSEcCtD
Cabergoline—Dizziness—Epirubicin—bone cancer	0.000192	0.00132	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—bone cancer	0.00019	0.00131	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—bone cancer	0.000184	0.00127	CcSEcCtD
Cabergoline—Nausea—Methotrexate—bone cancer	0.000184	0.00127	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—bone cancer	0.000184	0.00126	CcSEcCtD
Cabergoline—Rash—Epirubicin—bone cancer	0.000183	0.00126	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—bone cancer	0.000183	0.00126	CcSEcCtD
Cabergoline—Headache—Epirubicin—bone cancer	0.000182	0.00125	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—bone cancer	0.000178	0.00122	CcSEcCtD
Cabergoline—Nausea—Epirubicin—bone cancer	0.000172	0.00119	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—bone cancer	0.000171	0.00117	CcSEcCtD
Cabergoline—Rash—Doxorubicin—bone cancer	0.000169	0.00117	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—bone cancer	0.000169	0.00116	CcSEcCtD
Cabergoline—Headache—Doxorubicin—bone cancer	0.000168	0.00116	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—bone cancer	0.000159	0.0011	CcSEcCtD
Cabergoline—ADRA1D—Signaling Pathways—IL3—bone cancer	3.02e-05	0.000377	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL3—bone cancer	3.02e-05	0.000377	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TGFBR2—bone cancer	3.02e-05	0.000377	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—GNA11—bone cancer	3.01e-05	0.000376	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—GNA11—bone cancer	2.97e-05	0.000371	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TGFBR2—bone cancer	2.95e-05	0.000369	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—DHFR—bone cancer	2.92e-05	0.000365	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TGFBR2—bone cancer	2.91e-05	0.000363	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—GNA11—bone cancer	2.9e-05	0.000363	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—GNA11—bone cancer	2.89e-05	0.000361	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IGF1R—bone cancer	2.86e-05	0.000357	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IGF1R—bone cancer	2.84e-05	0.000355	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—ATF1—bone cancer	2.82e-05	0.000353	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—GNA11—bone cancer	2.81e-05	0.000351	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—ATF1—bone cancer	2.79e-05	0.000349	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SMO—bone cancer	2.79e-05	0.000348	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IGF1R—bone cancer	2.78e-05	0.000347	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TGFBR2—bone cancer	2.77e-05	0.000347	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—GNA11—bone cancer	2.76e-05	0.000345	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—ATF1—bone cancer	2.76e-05	0.000345	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL3—bone cancer	2.75e-05	0.000344	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SMO—bone cancer	2.74e-05	0.000343	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IGF1R—bone cancer	2.73e-05	0.000342	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—GNA11—bone cancer	2.73e-05	0.000341	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL3—bone cancer	2.73e-05	0.000341	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—ATF1—bone cancer	2.7e-05	0.000337	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL3—bone cancer	2.69e-05	0.000336	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—KIT—bone cancer	2.69e-05	0.000336	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SMO—bone cancer	2.68e-05	0.000336	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—ATF1—bone cancer	2.68e-05	0.000336	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL3—bone cancer	2.63e-05	0.000329	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL3—bone cancer	2.62e-05	0.000327	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TGFBR2—bone cancer	2.62e-05	0.000327	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IGF1R—bone cancer	2.61e-05	0.000326	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—ATF1—bone cancer	2.61e-05	0.000326	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—GSTP1—bone cancer	2.6e-05	0.000326	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TGFBR2—bone cancer	2.58e-05	0.000323	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TGFBR2—bone cancer	2.58e-05	0.000323	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—ATF1—bone cancer	2.57e-05	0.000321	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—GNA11—bone cancer	2.55e-05	0.000319	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL3—bone cancer	2.55e-05	0.000318	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—BRAF—bone cancer	2.53e-05	0.000316	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—GNA11—bone cancer	2.51e-05	0.000313	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL3—bone cancer	2.51e-05	0.000313	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SMO—bone cancer	2.49e-05	0.000312	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—CYP3A4—bone cancer	2.47e-05	0.000309	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IGF1R—bone cancer	2.46e-05	0.000308	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—GNA11—bone cancer	2.45e-05	0.000307	CbGpPWpGaD
Cabergoline—DRD5—Signaling by GPCR—EGFR—bone cancer	2.45e-05	0.000306	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IGF1R—bone cancer	2.43e-05	0.000304	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IGF1R—bone cancer	2.43e-05	0.000304	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—ATF1—bone cancer	2.37e-05	0.000296	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFBR2—bone cancer	2.35e-05	0.000294	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFBR2—bone cancer	2.33e-05	0.000291	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—ATF1—bone cancer	2.33e-05	0.000291	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL3—bone cancer	2.31e-05	0.000289	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFBR2—bone cancer	2.3e-05	0.000288	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—ATF1—bone cancer	2.28e-05	0.000285	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—GNA11—bone cancer	2.28e-05	0.000285	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL3—bone cancer	2.27e-05	0.000284	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFBR2—bone cancer	2.25e-05	0.000281	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFBR2—bone cancer	2.24e-05	0.00028	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL3—bone cancer	2.23e-05	0.000278	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IGF1R—bone cancer	2.21e-05	0.000277	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IGF1R—bone cancer	2.19e-05	0.000274	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	2.18e-05	0.000272	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IGF1R—bone cancer	2.17e-05	0.000271	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	2.14e-05	0.000268	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—ATF1—bone cancer	2.12e-05	0.000265	CbGpPWpGaD
Cabergoline—ADRA2B—Hemostasis—TP53—bone cancer	2.12e-05	0.000265	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IGF1R—bone cancer	2.12e-05	0.000265	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—MDM2—bone cancer	2.12e-05	0.000265	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—GSTP1—bone cancer	2.12e-05	0.000264	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IGF1R—bone cancer	2.11e-05	0.000263	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—KIT—bone cancer	2.07e-05	0.000259	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL3—bone cancer	2.07e-05	0.000258	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—KIT—bone cancer	2.06e-05	0.000257	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IGF1R—bone cancer	2.05e-05	0.000256	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IGF1R—bone cancer	2.02e-05	0.000252	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—KIT—bone cancer	2.02e-05	0.000252	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—KIT—bone cancer	1.98e-05	0.000248	CbGpPWpGaD
Cabergoline—ADRA2C—Hemostasis—TP53—bone cancer	1.98e-05	0.000248	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFBR2—bone cancer	1.98e-05	0.000247	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—BRAF—bone cancer	1.95e-05	0.000243	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFBR2—bone cancer	1.94e-05	0.000243	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—BRAF—bone cancer	1.93e-05	0.000242	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	1.9e-05	0.000238	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—BRAF—bone cancer	1.89e-05	0.000237	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—KIT—bone cancer	1.89e-05	0.000237	CbGpPWpGaD
Cabergoline—HTR7—Signaling by GPCR—EGFR—bone cancer	1.89e-05	0.000236	CbGpPWpGaD
Cabergoline—HTR1D—Signaling by GPCR—EGFR—bone cancer	1.88e-05	0.000234	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—BRAF—bone cancer	1.86e-05	0.000233	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IGF1R—bone cancer	1.86e-05	0.000232	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—JUN—bone cancer	1.84e-05	0.00023	CbGpPWpGaD
Cabergoline—HTR1B—Signaling by GPCR—EGFR—bone cancer	1.84e-05	0.00023	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IGF1R—bone cancer	1.83e-05	0.000229	CbGpPWpGaD
Cabergoline—DRD4—Signaling by GPCR—EGFR—bone cancer	1.81e-05	0.000226	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IGF1R—bone cancer	1.79e-05	0.000224	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—MMP9—bone cancer	1.79e-05	0.000224	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KIT—bone cancer	1.79e-05	0.000223	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—BRAF—bone cancer	1.78e-05	0.000222	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	1.77e-05	0.000221	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KIT—bone cancer	1.76e-05	0.00022	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KIT—bone cancer	1.76e-05	0.00022	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—EGFR—bone cancer	1.73e-05	0.000216	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—BRAF—bone cancer	1.68e-05	0.00021	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IGF1R—bone cancer	1.66e-05	0.000208	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—BRAF—bone cancer	1.66e-05	0.000207	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—BRAF—bone cancer	1.66e-05	0.000207	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—MDM2—bone cancer	1.63e-05	0.000204	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—EGFR—bone cancer	1.63e-05	0.000203	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—MDM2—bone cancer	1.62e-05	0.000203	CbGpPWpGaD
Cabergoline—ADRA2A—Hemostasis—TP53—bone cancer	1.61e-05	0.000201	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KIT—bone cancer	1.61e-05	0.000201	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—EGFR—bone cancer	1.61e-05	0.000201	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—EGFR—bone cancer	1.61e-05	0.000201	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KIT—bone cancer	1.59e-05	0.000199	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—MDM2—bone cancer	1.59e-05	0.000198	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KIT—bone cancer	1.57e-05	0.000196	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—MDM2—bone cancer	1.56e-05	0.000195	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KIT—bone cancer	1.54e-05	0.000192	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KIT—bone cancer	1.53e-05	0.000191	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—BRAF—bone cancer	1.51e-05	0.000189	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—BRAF—bone cancer	1.5e-05	0.000187	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—MDM2—bone cancer	1.49e-05	0.000186	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KIT—bone cancer	1.49e-05	0.000186	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—BRAF—bone cancer	1.48e-05	0.000185	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—EGFR—bone cancer	1.46e-05	0.000183	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KIT—bone cancer	1.46e-05	0.000183	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—EGFR—bone cancer	1.45e-05	0.000181	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—EGFR—bone cancer	1.45e-05	0.000181	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—BRAF—bone cancer	1.44e-05	0.00018	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—BRAF—bone cancer	1.44e-05	0.000179	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—EGFR—bone cancer	1.43e-05	0.000179	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—JUN—bone cancer	1.42e-05	0.000177	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—JUN—bone cancer	1.41e-05	0.000176	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MDM2—bone cancer	1.41e-05	0.000176	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—EGFR—bone cancer	1.4e-05	0.000175	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—BRAF—bone cancer	1.4e-05	0.000175	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.39e-05	0.000174	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MDM2—bone cancer	1.39e-05	0.000173	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MDM2—bone cancer	1.39e-05	0.000173	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—MMP9—bone cancer	1.38e-05	0.000173	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—JUN—bone cancer	1.38e-05	0.000172	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—BRAF—bone cancer	1.37e-05	0.000172	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—MMP9—bone cancer	1.37e-05	0.000171	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—JUN—bone cancer	1.36e-05	0.00017	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—EGFR—bone cancer	1.35e-05	0.000169	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PTGS2—bone cancer	1.35e-05	0.000169	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KIT—bone cancer	1.35e-05	0.000169	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—MMP9—bone cancer	1.34e-05	0.000168	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ENO2—bone cancer	1.34e-05	0.000168	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—EGFR—bone cancer	1.33e-05	0.000167	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KIT—bone cancer	1.33e-05	0.000166	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—MMP9—bone cancer	1.32e-05	0.000165	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KIT—bone cancer	1.3e-05	0.000162	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—JUN—bone cancer	1.3e-05	0.000162	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—BRAF—bone cancer	1.27e-05	0.000158	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MDM2—bone cancer	1.26e-05	0.000158	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—MMP9—bone cancer	1.26e-05	0.000158	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MDM2—bone cancer	1.25e-05	0.000157	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—BRAF—bone cancer	1.25e-05	0.000156	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—DHFR—bone cancer	1.24e-05	0.000155	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MDM2—bone cancer	1.24e-05	0.000155	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—EGFR—bone cancer	1.23e-05	0.000154	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—JUN—bone cancer	1.22e-05	0.000153	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—BRAF—bone cancer	1.22e-05	0.000153	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—TP53—bone cancer	1.21e-05	0.000152	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MDM2—bone cancer	1.21e-05	0.000151	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—EGFR—bone cancer	1.21e-05	0.000151	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KIT—bone cancer	1.21e-05	0.000151	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—JUN—bone cancer	1.21e-05	0.000151	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—JUN—bone cancer	1.21e-05	0.000151	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MDM2—bone cancer	1.2e-05	0.00015	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MMP9—bone cancer	1.19e-05	0.000149	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—EGFR—bone cancer	1.18e-05	0.000148	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MMP9—bone cancer	1.17e-05	0.000147	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MMP9—bone cancer	1.17e-05	0.000147	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MDM2—bone cancer	1.17e-05	0.000146	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GNA11—bone cancer	1.16e-05	0.000145	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MDM2—bone cancer	1.15e-05	0.000144	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—BRAF—bone cancer	1.13e-05	0.000142	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—EGFR—bone cancer	1.12e-05	0.000139	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—EGFR—bone cancer	1.11e-05	0.000138	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—EGFR—bone cancer	1.1e-05	0.000137	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—JUN—bone cancer	1.1e-05	0.000137	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTGS2—bone cancer	1.1e-05	0.000137	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—JUN—bone cancer	1.09e-05	0.000136	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—EGFR—bone cancer	1.08e-05	0.000136	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—JUN—bone cancer	1.07e-05	0.000134	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MMP9—bone cancer	1.07e-05	0.000134	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—EGFR—bone cancer	1.07e-05	0.000133	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MDM2—bone cancer	1.06e-05	0.000133	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MMP9—bone cancer	1.06e-05	0.000132	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—JUN—bone cancer	1.05e-05	0.000131	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MMP9—bone cancer	1.05e-05	0.000131	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—JUN—bone cancer	1.05e-05	0.000131	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MDM2—bone cancer	1.04e-05	0.000131	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MDM2—bone cancer	1.02e-05	0.000128	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MMP9—bone cancer	1.02e-05	0.000128	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—EGFR—bone cancer	1.02e-05	0.000127	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MMP9—bone cancer	1.02e-05	0.000127	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—JUN—bone cancer	1.02e-05	0.000127	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—JUN—bone cancer	1e-05	0.000125	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MMP9—bone cancer	9.9e-06	0.000124	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MMP9—bone cancer	9.74e-06	0.000122	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—EGFR—bone cancer	9.61e-06	0.00012	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MDM2—bone cancer	9.5e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—EGFR—bone cancer	9.48e-06	0.000119	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—EGFR—bone cancer	9.48e-06	0.000119	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—bone cancer	9.36e-06	0.000117	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—bone cancer	9.3e-06	0.000116	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—JUN—bone cancer	9.23e-06	0.000115	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—bone cancer	9.11e-06	0.000114	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—JUN—bone cancer	9.08e-06	0.000114	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTP1—bone cancer	9.01e-06	0.000113	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—bone cancer	8.98e-06	0.000112	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—bone cancer	8.96e-06	0.000112	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—JUN—bone cancer	8.89e-06	0.000111	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—bone cancer	8.83e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—bone cancer	8.65e-06	0.000108	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—bone cancer	8.64e-06	0.000108	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—bone cancer	8.56e-06	0.000107	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—bone cancer	8.56e-06	0.000107	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—bone cancer	8.45e-06	0.000106	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—bone cancer	8.26e-06	0.000103	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—JUN—bone cancer	8.26e-06	0.000103	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—bone cancer	8.22e-06	0.000103	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—bone cancer	8.07e-06	0.000101	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—bone cancer	8.04e-06	0.0001	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—bone cancer	8e-06	0.0001	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—bone cancer	7.96e-06	9.95e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—bone cancer	7.96e-06	9.95e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—bone cancer	7.87e-06	9.84e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—bone cancer	7.26e-06	9.07e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—bone cancer	7.25e-06	9.07e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—bone cancer	7.19e-06	8.98e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—bone cancer	7.14e-06	8.92e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—bone cancer	7.1e-06	8.87e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—bone cancer	6.99e-06	8.74e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—bone cancer	6.94e-06	8.67e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—bone cancer	6.9e-06	8.63e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—bone cancer	6.71e-06	8.39e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—bone cancer	6.61e-06	8.26e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—bone cancer	6.5e-06	8.12e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—bone cancer	6.09e-06	7.62e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—bone cancer	5.99e-06	7.49e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—bone cancer	5.87e-06	7.34e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—bone cancer	5.45e-06	6.82e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—bone cancer	4.67e-06	5.84e-05	CbGpPWpGaD
